CN Patent

CN119950682A — 用于药物治疗的司美鲁肽

Assigned to Novo Nordisk AS · Expires 2025-05-09 · 1y expired

What this patent protects

本发明涉及用于药物治疗的司美鲁肽，该药物治疗是体重管理的形式，包括肥胖症的治疗。

USPTO Abstract

本发明涉及用于药物治疗的司美鲁肽，该药物治疗是体重管理的形式，包括肥胖症的治疗。

Drugs covered by this patent

Patent Metadata

Patent number
CN119950682A
Jurisdiction
CN
Classification
—
Expires
2025-05-09
Drug substance claim
No
Drug product claim
No
Assignee
Novo Nordisk AS
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.